| Previous close | 2.2500 |
| Open | 2.4300 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 155.00 |
| Expiry date | 2024-06-07 |
| Day's range | 1.6000 - 2.4700 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
PR NewswireAbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform
AbbVie (NYSE: ABBV) today announced that new data from its innovative antibody-drug conjugate (ADC) platform will be showcased across three oral presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (May 31 - June 4, 2024). AbbVie's ADCs are designed to target unique protein biomarkers such as c-Met (MET protein) and SEZ6 (seizure-related homolog 6 protein), which are over-expressed across various tumor types. By utilizing these biomarkers as targets, ADCs are
- PR Newswire
AbbVie Completes Acquisition of Landos Biopharma
AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP). With the completion of the acquisition, Landos is now part of AbbVie.
ZacksWhy AbbVie (ABBV) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
